Non-Coding RNAs in Gastric Cancer: From Malignant Hallmarks to Clinical Applications

Chen, Di; Shuai, Ping; Xu, Yushuang; Wang, Mengmeng; Jiang, Xin; Xiong, Lina; Zhang, Li; Yu, Honglu; Xiong, Zhifan

doi:10.3389/fcell.2021.732036

Cited by 11 publications

(11 citation statements)

References 177 publications

(211 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Based on the association observed between lncRNA and GC progression, it is possible to assume that specific lncRNAs will shortly be used as clinical biomarkers for the diagnosis and prognosis of GC patients. In addition, lncRNAs are also recognized as therapeutic targets or therapeutic agents for GC patients (21). Compared with proteincoding genes, lncRNA therapy exhibits several advantages: Firstly, lncRNAs are highly abundantly expressed in humans with about 5,400 to more than 10,000 lncRNA transcripts (162), indicating that lncRNAs could be more accessible targets for cancer therapy.…”

Section: Conclusion and Perspectivementioning

confidence: 99%

“…In fact, the aberrant expression of lncRNAs has been observed in GC samples and cell lines (17,18). A growing amount of evidence suggests that lncRNAs are involved in practically all aspects of GC progression, including drug resistance (19)(20)(21). Exosomes are a novel extracellular vesicles that play crucial roles in cancer progression by transferring multiple biologically active molecules, such as proteins, lipids, and lncRNAs.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Long Non-Coding RNA in Gastric Cancer: Mechanisms and Clinical Implications for Drug Resistance

Liu

Yü

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

Gastric cancer (GC) is the third leading cause of cancer-related deaths worldwide, with high recurrence and mortality rate. Chemotherapy, including 5-fluorouracil (5-FU), adriamycin (ADR), vincristine (VCR), paclitaxel (PTX), and platinum drugs, remains one of the fundamental methods of GC treatment and has efficiently improved patients’ prognosis. However, most patients eventually develop resistance to chemotherapeutic agents, leading to the failure of clinical treatment and patients’ death. Recent studies suggest that long non-coding RNAs (lncRNAs) are involved in the drug resistance of GC by modulating the expression of drug resistance-related genes via sponging microRNAs (miRNAs). Moreover, lncRNAs also play crucial roles in GC drug resistance via a variety of mechanisms, such as the regulation of the oncogenic signaling pathways, inhibition of apoptosis, induction of autophagy, modulation of cancer stem cells (CSCs), and promotion of the epithelial-to-mesenchymal transition (EMT) process. Some of lncRNAs exhibit great potential as diagnostic and prognostic biomarkers, as well as therapeutic targets for GC patients. Therefore, understanding the role of lncRNAs and their mechanisms in GC drug resistance may provide us with novel insights for developing strategies for individual diagnosis and therapy. In this review, we summarize the recent findings on the mechanisms underlying GC drug resistance regulated by lncRNAs. We also discuss the potential clinical applications of lncRNAs as biomarkers and therapeutic targets in GC.

show abstract

Section: Conclusion and Perspectivementioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Long Non-Coding RNA in Gastric Cancer: Mechanisms and Clinical Implications for Drug Resistance

Liu

Yü

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…The global incidence of stomach cancer estimated in 2020 was approximately 1089100 new cases and 768800 cancer deaths ( Figure 1 ). In recent years, a rising body of evidence has revealed that miRs are dysregulated in almost all types of tumors, including gastric, modulating the proliferation, stemness, tumor immune escape, invasion, angiogenesis, and drug resistance of tumor cells ( Chen et al, 2021 ). Some studies in which miRs play a major role in mediating DDP-resistance in stomach cancer will be detailed in Table 3 .…”

Section: The Top Five Deadliest Cancermentioning

confidence: 99%

Contribution of MicroRNAs in Chemoresistance to Cisplatin in the Top Five Deadliest Cancer: An Updated Review

Loren

Saavedra

et al. 2022

Front. Pharmacol.

View full text Add to dashboard Cite

Cisplatin (DDP) is a well-known anticancer drug used for the treatment of numerous human cancers in solid organs, including bladder, breast, cervical, head and neck squamous cell, ovarian, among others. Its most important mode of action is the DNA-platinum adducts formation, inducing DNA damage response, silencing or activating several genes to induce apoptosis; these mechanisms result in genetics and epigenetics modifications. The ability of DDP to induce tumor cell death is often challenged by the presence of anti-apoptotic regulators, leading to chemoresistance, wherein many patients who have or will develop DDP-resistance. Cancer cells resist the apoptotic effect of chemotherapy, being a problem that severely restricts the successful results of treatment for many human cancers. In the last 30 years, researchers have discovered there are several types of RNAs, and among the most important are non-coding RNAs (ncRNAs), a class of RNAs that are not involved in protein production, but they are implicated in gene expression regulation, and representing the 98% of the human genome non-translated. Some ncRNAs of great interest are long ncRNAs, circular RNAs, and microRNAs (miRs). Accumulating studies reveal that aberrant miRs expression can affect the development of chemotherapy drug resistance, by modulating the expression of relevant target proteins. Thus, identifying molecular mechanisms underlying chemoresistance development is fundamental for setting strategies to improve the prognosis of patients with different types of cancer. Therefore, this review aimed to identify and summarize miRs that modulate chemoresistance in DDP-resistant in the top five deadliest cancer, both in vitro and in vivo human models.

show abstract

“…In addition, accumulating studies identify non-coding RNAs including micro (mi)RNA, circular (circ)RNA and long-noncoding RNA as having prognostic value. Although studies highlight the value of biomarkers, some limitations cannot be ignored, such as conclusions based on a single research cohort, inadequate multi-center validation, single marker, and small sample sizes (9)(10)(11)(12). Therefore, new biomarkers with high accuracy and specificity are needed to improve the diagnosis and prognosis of GC.…”

Section: Introductionmentioning

confidence: 99%

Comprehensive analysis of competitive endogenous RNAs network: Identification and validation of prediction model composed of mRNA signature and miRNA signature in gastric cancer

Ding

et al. 2022

Oncol Lett

View full text Add to dashboard Cite

Gastric cancer (GC), one of the most lethal malignant tumors, is highly aggressive with a poor prognosis, while the molecular mechanisms underlying it remain largely unknown. Although advanced imaging techniques and comprehensive treatment facilitate the diagnosis and survival of some GC patients, the precise diagnosis and prognosis are still a challenge. The present study used publicly available gene expression profiles from The Cancer Genome Atlas and Gene Expression Omnibus datasets including mRNA, micro (mi)RNA and circular (circ)RNA of GC to establish a competing endogenous RNA network (ceRNA). Further, the present study performed least absolute shrinkage and selector operator regression analysis on the hub RNAs to establish a prediction model with mRNA and miRNA. The ceRNA network contained 109 edges and 56 nodes and the visible network contains 13 miRNAs, 9 circRNAs and 34 mRNAs. The five mRNA-based signature were CTF1, FKBP5, RNF128, GSTM2 and ADAMTS1. The area under curve (AUC) value of the diagnosis training cohort was 0.9975. The prognosis of the high-risk group (RiskScore >4.664) was worse compared with that of the low-risk group (RiskScore ≤4.664; P<0.05) in the training cohort. The five miRNA-based signature were miR-145-5p, miR-615-3p, miR-6507-5p, miR-937-3p and miR-99a-3p. The AUC value of the diagnosis training cohort was 0.9975. The prognosis of the high-risk group (RiskScore >1.621) was worse compared with that of the low-risk group (RiskScore ≤1.621; P<0.05) in the training cohort. The validation cohorts indicated that both five mRNA and five miRNA-based signatures had strong predictive power in diagnosis and prognosis for GC. In conclusion, a ceRNA network was established for GC and a five mRNA-based signature and a five miRNA-based signature was identified that enabled diagnosis and prognosis of GC by assigning patient to a high-risk group or low-risk group.

show abstract

Non-Coding RNAs in Gastric Cancer: From Malignant Hallmarks to Clinical Applications

Cited by 11 publications

References 177 publications

Long Non-Coding RNA in Gastric Cancer: Mechanisms and Clinical Implications for Drug Resistance

Long Non-Coding RNA in Gastric Cancer: Mechanisms and Clinical Implications for Drug Resistance

Contribution of MicroRNAs in Chemoresistance to Cisplatin in the Top Five Deadliest Cancer: An Updated Review

Comprehensive analysis of competitive endogenous RNAs network: Identification and validation of prediction model composed of mRNA signature and miRNA signature in gastric cancer

Contact Info

Product

Resources

About